University of Ioannina

About: University of Ioannina is a education organization based out in Ioannina, Greece. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 7654 authors who have published 20594 publications receiving 671560 citations. The organization is also known as: Panepistimio Ioanninon.

Enhanced Fracture Properties of Carbon Reinforced Composites by the Addition of Multi-Wall Carbon Nanotubes

Abstract: In the present study, the fracture energy of hybrid carbon fiber reinforced polymers was investigated. The composites were modified by the addition of multi-walled carbon nanotubes into the matrix material. The interlaminar fracture properties under Mode I and Mode II remote loading were studied as a function of the carbon nanotube content in the matrix. With the addition of carbon nanotubes in the epoxy matrix, a significant increase in the load bearing ability as well as in the fracture energy was observed, for both Mode I and Mode II tests. It is speculated that carbon nanotubes due to their large aspect ratio have a significant toughening effect since extra energy is needed in order to pull them out from the matrix and start the crack propagation following a kinking out pattern at nanoscale.

A practical introduction to multivariate meta-analysis.

Abstract: Multivariate meta-analysis is becoming increasingly popular and official routines or self-programmed functions have been included in many statistical software. In this article, we review the statistical methods and the related software for multivariate meta-analysis. Emphasis is placed on Bayesian methods using Markov chain Monte Carlo, and codes in WinBUGS are provided. The various model-fitting options are illustrated in two examples and specific guidance is provided on how to run a multivariate meta-analysis using various software packages.

Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience.

Abstract: BACKGROUND The objective of this study was to estimate the incidence and describe distribution, clinical presentation, and prognosis of brain metastases in patients with prostrate carcinoma who were seen at The University of Texas M. D. Anderson Cancer Center (MDACC). METHODS The authors reviewed the charts of 16,280 patients with prostate carcinoma in the MDACC patient data base. Of 131 patients with craniospinal metastases confirmed by neuroimaging (n = 53 patients) or autopsy (n = 78 patients), 103 of 16,280 patients (0.63%) had parenchymal metastases. RESULTS The median patient age at diagnosis was 64 years (range, 16–85 years). The median interval from the diagnosis of prostate carcinoma to the detection of brain metastasis was 35 months for patients with adenocarcinoma and 48 months for patients with small cell carcinoma (SCC). Confusion, headache, and memory deficits were the most frequent initial symptoms. Eighty-six percent of patients had single lesions, and 14% of patients had ≥ 2 lesions. Metastases were supratentorial in 81 of 103 patients (76%), infratentorial in 22 of 103 patients (21%), and both supratentorial and infratentorial in 3 of 103 patients (3%). SCC and cribriform subtypes were more likely than adenocarcinoma to metastasize to the brain (relative risk, 20.36; 95% confidence interval, 9.91–41.84). Regardless of histology, the median survival in untreated patients was 1 month compared with 3.5 months in patients who were treated with radiotherapy. Patients who underwent stereotactic radiosurgery (n = 5 patients) had a longer median survival (9 months). Survival was not affected by supratentorial or infratentorial location of metastases. CONCLUSIONS Brain metastasis from prostate carcinoma is a rare, terminal event with death in < 1 year frequently due to advanced, systemic disease. The majority of metastases were single and supratentorial. The most common clinical presentation was nonfocal neurologic symptoms related to intracranial hypertension. A better understanding of the biology of prostate carcinoma will help clarify the basis for its metastasis to the brain. Cancer 2003;98:363–8. © 2003 American Cancer Society. DOI 10.1002/cncr.11522